Article Text

Download PDFPDF

46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
  1. Junzhu Xu1,
  2. Benjamin Frey2,
  3. Hu Ma1,
  4. Udo Gaipl2 and
  5. Jian-Guo Zhou3
  1. 1The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
  2. 2Universitätsklinikum Erlangen, Nuremberg, Erlangen, Germany
  3. 3Zunyi Medical University, Zunyi, Guizhou, China


Background Remarkable breakthroughs in immune checkpoint inhibitors (ICIs) for treating driverless target lung cancers have resulted in significant patient survival benefits. However, the efficacy of this approach in lung cancer patients with HER2 mutation remains debatable.

Methods Through retrospective analysis of pooled data from two large randomized trials, Phase II POPLAR (NCT01903993) and Phase III OAK (NCT02008227), we identified 1137 cases of previously treated non-small cell lung cancer (NSCLC) with sufficient blood specimens for bTMB testing who randomly assigned to receive atezolizumab (n =429) or docetaxel (n =708). The primary objective of this analysis was to assess the efficacy of immunotherapy in HER2-positive patients.

Results A total of 35 of all patients were HER2 positive (35/1137, 3.07%). Of these patients receiving immunotherapy (n=11) and chemotherapy (n=24), mPFS was 4.21 and 5.17 months, respectively [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.25–1.3]. No significant correlation between HER2 positivity and the efficacy of chemotherapy and immunotherapy. Multivariate analysis also showed no significant correlation between HER2 positivity and PFS or OS in all patients receiving immunotherapy (n=429). The mPFS for HER2-positive (n=10) versus HER2-negative (n=419) patients was 2.84m, 2.73m (HR 0.89, 95% CI 0.44–1.8) and mOS was 15.5m, 12.6m (HR 0.68, 95% CI 0.28–1.65). In addition, bTMB-high had a longer mOS compared to bTMB-low in both the allimmunotherapy population and HER2-positive patients (13.24 vs. 9.49 months, P < 0.05; 11.14 vs. 6.49 months, P < 0.05). The bTMB is a predictive biomarker for OS in atezolizumab-treated NSCLC patients compared to docetaxel-treated patients (bTMB-high: HR Ate vs. Dtx = 1.47 [95% CI: 0.60–3.58], P = 0.401; bTMB-low: HR Ate vs. Dtx = 0.56 [95% CI: 0.20–1.59], P = 0.279).

Conclusions Regardless of docetaxel and atezolizumab in second-line were less effective in HER2-positive NSCLC patients. However, bTMB is a potential biomarker for immunotherapy in HER2-positive NSCLC.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.